<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218438</url>
  </required_header>
  <id_info>
    <org_study_id>170904</org_study_id>
    <nct_id>NCT01218438</nct_id>
  </id_info>
  <brief_title>Phase 2/3 Study of IGSC, 20% in PIDD</brief_title>
  <official_title>A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation
      for the treatment of patients with primary immunodeficiency diseases (PIDD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Acute Serious Bacterial Infections Per Year (ASBI)</measure>
    <time_frame>1 year</time_frame>
    <description>Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant.
The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of All Infections Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Sinus Infections Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Fever Episodes Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Days on Antibiotics Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Hospitalizations for Illness or Infection Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)</measure>
    <time_frame>Epoch 1: 3 week IV administration interval: Week 10, 11, 12, 13. Epoch 1: 4 week IV interval: Week 9, 10, 11, 12, 13. Epoch 4 Subcutaneous administration weeks 17, 18</time_frame>
    <description>IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution;
AUCSC = area under the concentration-time curve following subcutaneous administration;
AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals</measure>
    <time_frame>Epoch 1: 3 week IV interval- weeks 0, 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 0, 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Anti-Tetanus Antibody</measure>
    <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Anti-Haemophilus Influenza B Antibody</measure>
    <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Anti-Hepatitis B Antibody</measure>
    <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)</measure>
    <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
    <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)</measure>
    <time_frame>29 weeks</time_frame>
    <description>There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals.
To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured.
The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4.
This was an interim study analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>Number of related SAEs and AEs divided by number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>Number of related SAEs and AEs divided by number of subjects and divided by number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>Number of all SAEs and AEs divided by number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>Number of all SAEs and AEs divided by number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant</measure>
    <time_frame>Within 72 hours of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion</measure>
    <time_frame>Within 72 hours of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant</measure>
    <time_frame>Within 24 hours of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion</measure>
    <time_frame>Within 24 hours of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant</measure>
    <time_frame>Within 1 hour of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion</measure>
    <time_frame>Within 1 hour of completion of infusion</time_frame>
    <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion</measure>
    <time_frame>Within 72 hours post infusion for Temporally Associated AEs; End of each Study Epoch (Epoch 1, Epoch 2, Epoch 3, and Epoch 4) for Causally Related AEs</time_frame>
    <description>The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion (&quot;temporally associated&quot;) plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug(&quot;related&quot;), divided by the total number of infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>The number of infusions associated with local non-SAEs divided by the total number of infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>An infusion will be deemed as tolerated unless one of the following occurs:
Any serious related AE(s)
Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion
Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term Tolerance - Change in Blood Pressure</measure>
    <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term Tolerance - Change in Heart Rate (Pulse)</measure>
    <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term Tolerance - Change in Respiratory Rate</measure>
    <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Term Tolerance - Change in Body Temperature</measure>
    <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration</measure>
    <time_frame>Epoch 1: 3 week IV interval- weeks 0, 10. Epoch 1: 4 week IV interval- weeks 0, 9. Epoch 3: Subcutaneous (SC) week 9. Epoch 4: SC weeks 17, 18, 40</time_frame>
    <description>Laboratory tests for confirmation of potential hemolysis include Coomb's test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>TSQM; for the age group 2 to 12 years the observer will be a parent.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>TSQM; for the age group 13 years and older the observer will be the participant.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Index - 2 to 12 Years Old</measure>
    <time_frame>Up to 20 months (throughout entire study)</time_frame>
    <description>For the age group 2 to 12 years the respondent will be a parent.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Index - 13 Years and Older</measure>
    <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
    <description>For the age group 13 years and older the respondent will be the participant.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <arm_group>
    <arm_group_label>Study Epochs 1-4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.
Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10% Solution</intervention_name>
    <description>Intravenous infusion with IGIV, 10%</description>
    <arm_group_label>Study Epochs 1-4</arm_group_label>
    <other_name>IGIV</other_name>
    <other_name>10%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin Subcutaneous (Human), 20% Solution</intervention_name>
    <description>Subcutaneous infusion with IGSC, 20%</description>
    <arm_group_label>Study Epochs 1-4</arm_group_label>
    <other_name>IGSC</other_name>
    <other_name>20%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Documented diagnosis of a form of primary humoral immunodeficiency involving defective
             antibody formation and requiring gammaglobulin replacement as defined according to the
             IUIS Scientific Committee, 2011 and by diagnostic criteria according to Conley et al.
             (1999). The diagnosis must be confirmed by the Medical Director prior to first
             treatment with the investigational product (IP) in the study.

          -  Participant is 2 years or older at the time of screening, and has a minimum body
             weight of 13 kg.

          -  Written informed consent has been obtained from either the participant or the
             participant's legally authorized representative prior to any study-related procedures
             and study product administration

          -  Participant has been receiving a stable monthly equivalent dose of IgG at an average
             minimum dose equivalent to 300 mg/kg bodyweight (BW)/4 weeks and a maximum dose
             equivalent to 1.0 gram/kg BW/4 weeks, for a minimum of 12 weeks prior to first
             treatment with the IP in the study.

          -  Serum trough level of IgG &gt; 500 mg/dL at screening

          -  Participant is willing and able to comply with the requirements of the protocol

        Main Exclusion Criteria:

          -  Participant has known history of or is positive at screening for one or more of the
             following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for
             Hepatitis C virus(HCV), PCR for human immunodeficiency virus (HIV) Type 1/2

          -  Abnormal laboratory values at screening meeting any one of the following criteria
             (abnormal tests may be repeated once to determine if they are persistent):

               -  Persistent alanine aminotransferase (ALT) and aspartate amino transferase(AST) &gt;
                  2.5 times the upper limit of normal for the testing laboratory

               -  Persistent severe neutropenia (defined as an absolute neutrophil count [ANC]
                  ≤500/mm^3)

          -  Creatinine clearance (CLcr) value that is &lt; 60% of normal for age and gender either
             measured, or calculated according to the Cockcroft-Gault formula

          -  Malignancy (other than adequately treated basal cell or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix), unless the disease-free period prior to
             screening exceeds 5 years

          -  Participant is receiving anti-coagulation therapy (low dose aspirin at ≤325 mg/day is
             permitted) or has a history of thrombotic episodes (including deep vein thrombosis,
             myocardial infarction, cerebrovascular accident, pulmonary embolism) or sickle cell
             disease with crisis within 12 months prior to screening or a history of thrombophilia

          -  Abnormal protein loss (protein losing enteropathy, nephrotic syndrome)

          -  Anemia that would preclude phlebotomy for laboratory studies according to standard
             practice at the site

          -  Acute serious bacterial infection within 3 months prior to screening

          -  Ongoing history of hypersensitivity or persistent reactions (urticaria, breathing
             difficulty, severe hypotension, or anaphylaxis) following intravenous immunoglobulin,
             subcutaneous immunoglobulin, and/or Immune Serum Globulin (ISG) infusions

          -  Severe immunoglobulin A (IgA) deficiency (less than 0.07g/L) with known anti-IgA
             antibodies and a history of hypersensitivity

          -  Participant is on continuous systemic antibacterial antibiotics at doses sufficient to
             treat or prevent bacterial infections, and, in the opinion of the investigator, cannot
             stop these for the duration of the study without putting the patient at risk of
             increased infections

          -  Participant has active infection and is receiving antibiotic therapy for the treatment
             of infection at the time of screening

          -  Bleeding disorder or thrombocytopenia with a platelet count less than 20,000/μL, or
             who, in the opinion of the investigator, would be at significant risk of increased
             bleeding or bruising as a result of subcutaneous therapy

          -  Total protein &gt; 9 g/dL or myeloma or macroglobulinemia (IgM) or paraproteinemia

          -  Severe dermatitis that would preclude adequate sites for safe product administration

          -  Women of childbearing potential meeting any one of the following criteria:

               -  Participant presents with a positive pregnancy test

               -  Participant is breast feeding

               -  Participant intends to begin nursing during the course of the study

               -  Participant does not agree to employ adequate birth-control measures (e.g.
                  intrauterine device, diaphragm or condom [for male partner] with spermicidal
                  jelly or foam, or birth control pills/patches) throughout the course of the study

          -  Participation in another clinical study and exposure to an investigational product or
             device within 30 days prior to study enrollment (exception: treatment in a previous
             Baxter immunoglobulin study)

          -  Participant is scheduled to participate in another (non-Baxter) non-observational
             (interventional) clinical study involving an investigational product or device during
             the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leman Yel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy and Asthma Research Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans- LSUHSC School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Immunology Clinical and Infusion Center</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Division of Allergy/Immunology</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy and Asthma Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, PC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Allergy Immunology Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma and Immunology Clinic PA</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Asthma/Allergy/Immunology</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital- McGill University health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>HEH 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarström L, Nonoyama S, Notarangelo LD, Ochs HD, Puck JM, Roifman CM, Seger R, Tang ML. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011 Nov 8;2:54. doi: 10.3389/fimmu.2011.00054. eCollection 2011.</citation>
    <PMID>22566844</PMID>
  </reference>
  <reference>
    <citation>Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999 Dec;93(3):190-7.</citation>
    <PMID>10600329</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <disposition_first_submitted>May 6, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>May 6, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 3, 2016</disposition_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled (signed informed consent) at 15 sites.</recruitment_details>
      <pre_assignment_details>A total of 86 participants provided informed consent. 9 of these participants did not start Epoch1, of which there were 6 screen failures; 2 were not able to receive their first infusion according to protocol timeline; and 1 withdrew. Therefore, 77 participants started Epoch 1 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Participants</title>
          <description>EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.
EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Epoch 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Epoch 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Epoch 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Epoch 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Dataset: All participants who received at least one dose of immunoglobulin.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Epochs 1-4</title>
          <description>EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.
EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" lower_limit="3" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Acute Serious Bacterial Infections Per Year (ASBI)</title>
        <description>Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant.
The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.</description>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Rate of Acute Serious Bacterial Infections Per Year (ASBI)</title>
          <description>Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per participant.
The observation period for each participant starts with the day of the first subcutaneous (SC) infusion in Study Epoch 2 and ends with the day of the End of Study visit.</description>
          <population>Safety Analysis Set</population>
          <units>Estimated infections/ year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>Poisson</param_type>
            <param_value>0.012</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of All Infections Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of All Infections Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated infections/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" lower_limit="2.77" upper_limit="5.22"/>
                    <measurement group_id="O2" value="2.41" lower_limit="1.89" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Sinus Infections Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Sinus Infections Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated infections/year</units>
          <param>Number</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.61" upper_limit="1.45"/>
                    <measurement group_id="O2" value="0.69" lower_limit="0.50" upper_limit="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Fever Episodes Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Fever Episodes Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated episodes/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.34" upper_limit="0.99"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.08" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Days Off School/Work or Days Unable to Perform Normal Daily Activities Due to Illness or Infection Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated days off/participant</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="1.88" upper_limit="5.03"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.70" upper_limit="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Days on Antibiotics Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Days on Antibiotics Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated days/particpant</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.20" lower_limit="43.39" upper_limit="88.29"/>
                    <measurement group_id="O2" value="57.59" lower_limit="40.71" upper_limit="78.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Hospitalizations for Illness or Infection Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Hospitalizations for Illness or Infection Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated hospitalizations/participant</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.02" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Days of Hospitalizations for Illness or Infection Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated days/participant</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.08" upper_limit="0.42"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.05" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant</title>
        <time_frame>1 year</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10% - Epoch 1</title>
            <description>- EPOCH 1: (13 weeks): Pharmacokinetics (PK) at 2nd to last infusion (participants ≥12 years of age). Participants will be treated with immune globulin administered intravenously (IGIV), 10% once every 3 or 4 weeks at same monthly equivalent dose as prior to study.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20% - Epochs 2 Thru 4</title>
            <description>EPOCH 2: (12-16 weeks): PK (first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated with immune globulin administered subcutaneously (IGSC), 20% every 7 days at dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
EPOCH 3: (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
EPOCH 4: (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Acute (Urgent or Unscheduled) Physician Visits, or Visits to the Emergency Room for Illness or Infection Per Participant</title>
          <population>Safety Analysis Set</population>
          <units>Estimated visits/participant</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.03" upper_limit="2.68"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.54" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)</title>
        <description>IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution;
AUCSC = area under the concentration-time curve following subcutaneous administration;
AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval</description>
        <time_frame>Epoch 1: 3 week IV administration interval: Week 10, 11, 12, 13. Epoch 1: 4 week IV interval: Week 9, 10, 11, 12, 13. Epoch 4 Subcutaneous administration weeks 17, 18</time_frame>
        <population>Safety Analysis Set with correctly administered IGIV 10% dose in Epoch 1</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epochs 1-4</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.
Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability of IGSC, 20% as Measured by the Ratio of the Geometric Means of Immunoglobulin G (IgG) AUCSC (Epoch 4) to IgG AUCIV,0-τ (Standardized to 1 Week) (Epoch 1) Adjusted for Dose and Dosing Frequency (Participants ≥12 Years Old)</title>
          <description>IGSC, 20% = Immune Globulin Subcutaneous (Human), 20% Solution;
AUCSC = area under the concentration-time curve following subcutaneous administration;
AUCIV,0-τ = area under the concentration-time curve following intravenous administration over a dosing interval</description>
          <population>Safety Analysis Set with correctly administered IGIV 10% dose in Epoch 1</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0855" lower_limit="1.0394" upper_limit="1.1336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals</title>
        <time_frame>Epoch 1: 3 week IV interval- weeks 0, 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 0, 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>IV 10% 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.
Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
          <group group_id="O2">
            <title>IV 10% 4 Weeks</title>
          </group>
          <group group_id="O3">
            <title>SC 20% 145% IV 1 Week</title>
          </group>
          <group group_id="O4">
            <title>SC 20% Adjusted 1 Week</title>
          </group>
          <group group_id="O5">
            <title>SC 20% Individualized 1 Week</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of IgG (Total), and IgG Subclasses at the End of the Treatment Intervals</title>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>g/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.58" lower_limit="10.36" upper_limit="12.94"/>
                    <measurement group_id="O2" value="10.19" lower_limit="9.55" upper_limit="10.88"/>
                    <measurement group_id="O3" value="14.77" lower_limit="13.86" upper_limit="15.74"/>
                    <measurement group_id="O4" value="14.20" lower_limit="13.48" upper_limit="14.96"/>
                    <measurement group_id="O5" value="14.74" lower_limit="14.03" upper_limit="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Subclass 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" lower_limit="5.47" upper_limit="7.09"/>
                    <measurement group_id="O2" value="5.45" lower_limit="5.04" upper_limit="5.91"/>
                    <measurement group_id="O3" value="8.06" lower_limit="7.51" upper_limit="8.65"/>
                    <measurement group_id="O4" value="7.83" lower_limit="7.33" upper_limit="8.38"/>
                    <measurement group_id="O5" value="7.41" lower_limit="6.98" upper_limit="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Subclass 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="3.53" upper_limit="4.35"/>
                    <measurement group_id="O2" value="3.30" lower_limit="3.08" upper_limit="3.54"/>
                    <measurement group_id="O3" value="4.83" lower_limit="4.47" upper_limit="5.21"/>
                    <measurement group_id="O4" value="4.95" lower_limit="4.65" upper_limit="5.26"/>
                    <measurement group_id="O5" value="4.94" lower_limit="4.69" upper_limit="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Subclass 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.352" lower_limit="0.285" upper_limit="0.435"/>
                    <measurement group_id="O2" value="0.405" lower_limit="0.347" upper_limit="0.473"/>
                    <measurement group_id="O3" value="0.516" lower_limit="0.463" upper_limit="0.574"/>
                    <measurement group_id="O4" value="0.514" lower_limit="0.458" upper_limit="0.578"/>
                    <measurement group_id="O5" value="0.514" lower_limit="0.456" upper_limit="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG Subclass 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" lower_limit="0.202" upper_limit="0.281"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.165" upper_limit="0.209"/>
                    <measurement group_id="O3" value="0.309" lower_limit="0.273" upper_limit="0.350"/>
                    <measurement group_id="O4" value="0.304" lower_limit="0.280" upper_limit="0.331"/>
                    <measurement group_id="O5" value="0.311" lower_limit="0.289" upper_limit="0.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Anti-Tetanus Antibody</title>
        <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Arm</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Anti-Tetanus Antibody</title>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study Medication- Epoch 1 Week 1 (N= 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" lower_limit="1.84" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="2.44" upper_limit="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="2.04" upper_limit="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks - Epoch 1 Week 10 (N= 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" lower_limit="1.83" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="1.52" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 5 (N= 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.44" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="1.79" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" lower_limit="1.84" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" lower_limit="3.12" upper_limit="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" lower_limit="3.32" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="3.21" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="2.64" upper_limit="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="2.39" upper_limit="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 9 (N=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" lower_limit="2.73" upper_limit="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 17(N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="2.74" upper_limit="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 29(N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" lower_limit="1.48" upper_limit="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week- End of Study (N= 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" lower_limit="1.66" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Anti-Haemophilus Influenza B Antibody</title>
        <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Arm</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Anti-Haemophilus Influenza B Antibody</title>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study Medication- Epoch 1 Week 1 (N= 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" lower_limit="2.55" upper_limit="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="2.07" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 7 (N= 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" lower_limit="2.36" upper_limit="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="1.75" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 13 (N= 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" lower_limit="1.85" upper_limit="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" lower_limit="2.30" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="2.23" upper_limit="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.20" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.44" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" lower_limit="3.30" upper_limit="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="3.12" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" lower_limit="3.10" upper_limit="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" lower_limit="3.06" upper_limit="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 9 (N=58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" lower_limit="3.87" upper_limit="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 17(N=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" lower_limit="4.21" upper_limit="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 29(N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" lower_limit="3.55" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week- End of Study (N= 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" lower_limit="4.48" upper_limit="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Anti-Hepatitis B Antibody</title>
        <time_frame>Epoch 1: 3 week IV interval- weeks 1, 4, 7, 10, 13. Epoch 1: 4 week IV interval- weeks 1, 5, 9, 13. Epochs 2 &amp; 3: Subcutaneous (SC) weeks 5, 9. Epoch 4: SC weeks 1, 9, 17, 29, 40 (week dependent on time to establish &quot;Adjusted Dose&quot; in Epoch 2)</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epochs 1-4</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.
Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Anti-Hepatitis B Antibody</title>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Study Medication- Epoch 1 Week 1 (N= 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.6" lower_limit="232.3" upper_limit="305.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 4 (N= 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.8" lower_limit="312.2" upper_limit="410.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 7 (N= 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.6" lower_limit="333.4" upper_limit="486.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 10 (N= 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.6" lower_limit="315.7" upper_limit="449.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 3 Weeks- Epoch 1 Week 13 (N= 16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.2" lower_limit="310.4" upper_limit="495.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 5 (N= 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.1" lower_limit="266.2" upper_limit="340.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 9 (N= 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.0" lower_limit="271.0" upper_limit="341.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV 10% 4 Weeks- Epoch 1 Week 13 (N= 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.3" lower_limit="266.0" upper_limit="330.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 5 (N= 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.7" lower_limit="425.0" upper_limit="506.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% 145% IV 1 Week- Epoch 2 Week 9 (N= 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525.0" lower_limit="478.1" upper_limit="576.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 5 (N= 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.9" lower_limit="533.4" upper_limit="634.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 3 Week 9 (N= 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.4" lower_limit="579.8" upper_limit="668.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% adjusted 1 Week- Epoch 4 Week 1 (N= 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.8" lower_limit="509.7" upper_limit="599.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 9(N= 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.4" lower_limit="400.4" upper_limit="471.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 17(N=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="444.5" lower_limit="408.2" upper_limit="484.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week Epoch 4 Week 29(N=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.2" lower_limit="355.9" upper_limit="425.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SC 20% individualized 1 Week- End of Study (N=56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.1" lower_limit="371.7" upper_limit="437.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)</title>
        <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study.
Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study.
Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Area Under the Curve (AUC)</title>
          <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week)</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>g*days/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.05" lower_limit="319.74" upper_limit="387.63"/>
                    <measurement group_id="O2" value="410.40" lower_limit="381.24" upper_limit="441.79"/>
                    <measurement group_id="O3" value="108.33" lower_limit="97.60" upper_limit="120.24"/>
                    <measurement group_id="O4" value="115.21" lower_limit="109.23" upper_limit="121.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)</title>
        <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Dose Per Weight-adjusted Area Under the Curve (AUC)</title>
          <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule. Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>(g*days/L)/(g/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.99" lower_limit="495.29" upper_limit="743.87"/>
                    <measurement group_id="O2" value="796.30" lower_limit="715.36" upper_limit="886.40"/>
                    <measurement group_id="O3" value="472.50" lower_limit="411.07" upper_limit="543.10"/>
                    <measurement group_id="O4" value="536.05" lower_limit="495.58" upper_limit="579.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)</title>
        <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time point</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance for Immune Globulin Administered Subcutaneously (IGSC)</title>
          <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0-τ). (F= bioavailability)</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time point</population>
          <units>mL/kg/days</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.34" upper_limit="2.02"/>
                    <measurement group_id="O2" value="1.26" lower_limit="1.13" upper_limit="1.40"/>
                    <measurement group_id="O3" value="2.12" lower_limit="1.84" upper_limit="2.43"/>
                    <measurement group_id="O4" value="1.87" lower_limit="1.72" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)</title>
        <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Week</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Maximum Concentration (Cmax)</title>
          <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>g/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.09" lower_limit="24.30" upper_limit="30.19"/>
                    <measurement group_id="O2" value="24.85" lower_limit="23.18" upper_limit="26.64"/>
                    <measurement group_id="O3" value="17.31" lower_limit="15.11" upper_limit="19.82"/>
                    <measurement group_id="O4" value="19.31" lower_limit="18.13" upper_limit="20.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)</title>
        <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Time to Maximum Concentration (Tmax)</title>
          <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>hours (h)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" lower_limit="3.96" upper_limit="12.17"/>
                    <measurement group_id="O2" value="5.84" lower_limit="3.62" upper_limit="9.40"/>
                    <measurement group_id="O3" value="54.19" lower_limit="36.28" upper_limit="80.92"/>
                    <measurement group_id="O4" value="78.68" lower_limit="65.37" upper_limit="94.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)</title>
        <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Immunoglobulin G (IgG): Minimum Concentration (Cmin)</title>
          <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>g/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.03" lower_limit="10.64" upper_limit="13.60"/>
                    <measurement group_id="O2" value="10.37" lower_limit="9.50" upper_limit="11.33"/>
                    <measurement group_id="O3" value="13.85" lower_limit="12.61" upper_limit="15.21"/>
                    <measurement group_id="O4" value="14.00" lower_limit="13.14" upper_limit="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)</title>
        <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Area Under the Curve (AUC)</title>
          <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week )</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mg*days/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.79" lower_limit="65.58" upper_limit="99.53"/>
                    <measurement group_id="O2" value="123.05" lower_limit="93.36" upper_limit="162.18"/>
                    <measurement group_id="O3" value="29.51" lower_limit="23.25" upper_limit="37.46"/>
                    <measurement group_id="O4" value="30.64" lower_limit="26.29" upper_limit="35.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)</title>
        <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Dose Per Weight-adjusted Area Under the Curve (AUC)</title>
          <description>The AUC between adjacent infusions will be calculated by the trapezoidal rule . Linear interpolation/extrapolation will be used to calculate the AUC for exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Epochs 1, 2 and 4, AUC 0-τ will be standardized for the infusion intervals (3 or 4 weeks vs. 1 week) adjusted for the dose per weight.</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>(mg*days/L)/(g/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.29" lower_limit="110.89" upper_limit="174.97"/>
                    <measurement group_id="O2" value="239.99" lower_limit="181.92" upper_limit="316.61"/>
                    <measurement group_id="O3" value="128.72" lower_limit="96.65" upper_limit="171.42"/>
                    <measurement group_id="O4" value="141.78" lower_limit="121.75" upper_limit="165.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously</title>
        <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 WeeksOverall Study Arm</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20%, 145% of IGIV 10%</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20%, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Clearance (CL) for Immune Globulin Administered Intravenously (IGIV) and Apparent Clearance (CL/F) for Immune Globulin Administered Subcutaneously</title>
          <description>Clearance (CL) or apparent clearance (CL/F) for IV and SC administration, respectively, will be determined by the formula: CL or CL/F = (Dose (mg/kg)) / (AUC 0- τ). (F= bioavailability)</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mL/kg/days</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.18" lower_limit="5.72" upper_limit="9.02"/>
                    <measurement group_id="O2" value="4.17" lower_limit="3.16" upper_limit="5.50"/>
                    <measurement group_id="O3" value="7.77" lower_limit="5.83" upper_limit="10.35"/>
                    <measurement group_id="O4" value="7.05" lower_limit="6.06" upper_limit="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)</title>
        <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20%, 145% of IGIV 10%</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Maximum Concentration (Cmax)</title>
          <description>The maximum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" lower_limit="5.25" upper_limit="7.59"/>
                    <measurement group_id="O2" value="7.22" lower_limit="5.75" upper_limit="9.05"/>
                    <measurement group_id="O3" value="4.40" lower_limit="3.45" upper_limit="5.62"/>
                    <measurement group_id="O4" value="4.86" lower_limit="4.16" upper_limit="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)</title>
        <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20 %, 145 % of IGIV 10 %</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20 %, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Time to Maximum Concentration (Tmax)</title>
          <description>The minimum time (Tmax) to reach the maximum concentration (Cmax)</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>Hours (s)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.69" upper_limit="3.59"/>
                    <measurement group_id="O2" value="3.71" lower_limit="2.69" upper_limit="5.12"/>
                    <measurement group_id="O3" value="70.67" lower_limit="51.14" upper_limit="97.66"/>
                    <measurement group_id="O4" value="66.87" lower_limit="56.22" upper_limit="79.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)</title>
        <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
        <time_frame>Epoch 1: 3 week IV interval: Weeks 10-13. Epoch 1: 4 week IV interval: Weeks 9-13. Epoch 2: Subcutaneous (SC) weeks 9-10. Epoch 4: SC weeks 17-18</time_frame>
        <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Study Epoch 1: IGIV 10% Every 3 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O2">
            <title>Study Epoch 1: IGIV 10% Every 4 Weeks</title>
            <description>Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 4 weeks at same monthly equivalent dose as prior to the study. Immune globulin administered intravenously (IGIV)</description>
          </group>
          <group group_id="O3">
            <title>Study Epoch 2: IGSC 20%, 145% of IGIV 10%</title>
            <description>Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1. Immune globulin administered subcutaneously (IGSC)</description>
          </group>
          <group group_id="O4">
            <title>Study Epoch 4: IGSC 20%, Individualized Dose</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion. Immune globulin administered subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters for Haemophilus Influenza B Antibody: Minimum Concentration (Cmin)</title>
          <description>The minimum concentration (Cmax) following administration of study drug (either immune globulin administered intravenously (IGIV) or immune globulin administered subcutaneously (IGSC).</description>
          <population>Safety Analysis Set - sub-groups with data at relevant time points</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" lower_limit="2.20" upper_limit="3.61"/>
                    <measurement group_id="O2" value="3.13" lower_limit="2.31" upper_limit="4.26"/>
                    <measurement group_id="O3" value="3.97" lower_limit="3.14" upper_limit="5.01"/>
                    <measurement group_id="O4" value="3.71" lower_limit="3.15" upper_limit="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)</title>
        <description>There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals.
To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured.
The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4.
This was an interim study analysis.</description>
        <time_frame>29 weeks</time_frame>
        <population>Pharmacokinetics interim analysis set to determine the Individually Adapted Dose for Epoch 4</population>
        <group_list>
          <group group_id="O1">
            <title>Correction Factor</title>
          </group>
        </group_list>
        <measure>
          <title>Correction Factor to Determine the Individually Adapted Dose in Study 170904 Epoch 4 (Dose Adjustment Table)</title>
          <description>There is a high degree of variability in catabolism of immunoglobulin G (IgG) between individuals.
To address this, trough levels immediately prior to the 9th weekly infusion in Epoch 3 were measured.
The ratio of the measured trough levels on subcutaneous (SC) (Epoch 3) and intravenous (IV) administration (Epoch1) were compared to the expected trough level determined in Epoch 2. This was used to determine the Individually Adapted Dose to be used in Epoch 4.
This was an interim study analysis.</description>
          <population>Pharmacokinetics interim analysis set to determine the Individually Adapted Dose for Epoch 4</population>
          <units>Correction factor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough Level Ratio: 0.93 or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 0.94</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 0.95 to 0.96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 0.97 to 0.98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 0.99 to 1.01</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.02 to 1.04</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.05 to 1.08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.09 to 1.13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.14 to 1.19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.20 to 1.26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.27 to 1.33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.34 to 1.40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.41 to 1.47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.48 to 1.55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough Level Ratio: 1.56 to 1.63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant</title>
        <description>Number of related SAEs and AEs divided by number of participants</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>INTRAVENOUS 10%</title>
          </group>
          <group group_id="O2">
            <title>SUBCUTANEOUS 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Participant</title>
          <description>Number of related SAEs and AEs divided by number of participants</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039"/>
                    <measurement group_id="O2" value="2.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039"/>
                    <measurement group_id="O2" value="2.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion</title>
        <description>Number of related SAEs and AEs divided by number of subjects and divided by number of infusions</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>INTRAVENOUS 10%</title>
          </group>
          <group group_id="O2">
            <title>SUBCUTANEOUS 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Deemed Related to the Investigational Product Per Infusion</title>
          <description>Number of related SAEs and AEs divided by number of subjects and divided by number of infusions</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per infusion</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247"/>
                    <measurement group_id="O2" value="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs -Excluding Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.247"/>
                    <measurement group_id="O2" value="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs -Excluding Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant</title>
        <description>Number of all SAEs and AEs divided by number of participants</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>INTRAVENOUS 10%</title>
          </group>
          <group group_id="O2">
            <title>SUBCUTANEOUS 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Participant</title>
          <description>Number of all SAEs and AEs divided by number of participants</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.325"/>
                    <measurement group_id="O2" value="9.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.338"/>
                    <measurement group_id="O2" value="6.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious (SAEs) and Non-serious Adverse Events (AEs) (Including and Excluding Infections) Regardless of Relationship to the Investigational Product Per Infusion</title>
        <description>Number of all SAEs and AEs divided by number of infusions</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant</title>
        <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants</description>
        <time_frame>Within 72 hours of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Participant</title>
          <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by number of participants</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.377"/>
                    <measurement group_id="O2" value="4.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.260"/>
                    <measurement group_id="O2" value="3.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion</title>
        <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions</description>
        <time_frame>Within 72 hours of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 72 Hours of Completion of Infusion Per Infusion</title>
          <description>Number of AEs that begin during or within 72 hours of completion of infusion divided by the number of infusions</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per infusion</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327"/>
                    <measurement group_id="O2" value="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.299"/>
                    <measurement group_id="O2" value="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant</title>
        <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants</description>
        <time_frame>Within 24 hours of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Participant</title>
          <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of participants</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.961"/>
                    <measurement group_id="O2" value="3.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948"/>
                    <measurement group_id="O2" value="3.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion</title>
        <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions</description>
        <time_frame>Within 24 hours of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 24 Hours of Completion of Infusion Per Infusion</title>
          <description>Number of AEs that begin during or within 24 hours of completion of infusion divided by number of infusions</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per infusion</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.228"/>
                    <measurement group_id="O2" value="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225"/>
                    <measurement group_id="O2" value="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant</title>
        <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants</description>
        <time_frame>Within 1 hour of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion Per Participant</title>
          <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of participants</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.662"/>
                    <measurement group_id="O2" value="1.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.662"/>
                    <measurement group_id="O2" value="1.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion</title>
        <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions</description>
        <time_frame>Within 1 hour of completion of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) (Including and Excluding Infections) That Begin During or Within 1 Hour of Completion of Infusion</title>
          <description>Number of AEs that begin during or within 1 hour of completion of infusion divided by number of infusions</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per infusion</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157"/>
                    <measurement group_id="O2" value="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157"/>
                    <measurement group_id="O2" value="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion</title>
        <description>The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion (&quot;temporally associated&quot;) plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug(&quot;related&quot;), divided by the total number of infusions</description>
        <time_frame>Within 72 hours post infusion for Temporally Associated AEs; End of each Study Epoch (Epoch 1, Epoch 2, Epoch 3, and Epoch 4) for Causally Related AEs</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Causally Related and/or Temporally Associated Adverse Events (AEs) Per Infusion</title>
          <description>The total number of all AEs (including and excluding infections) that begin during infusion or within 72 hours of completion of an infusion (&quot;temporally associated&quot;) plus the total number of AEs (including and excluding infections) starting more than 72 hours following the completion of an infusion determined by the investigator to be at least possibly related to the study drug(&quot;related&quot;), divided by the total number of infusions</description>
          <population>Safety Analysis Set</population>
          <units>Adverse events per infusion</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.336"/>
                    <measurement group_id="O2" value="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309"/>
                    <measurement group_id="O2" value="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Including infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs - Excluding infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)</title>
        <description>The number of infusions associated with local non-SAEs divided by the total number of infusions.</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infusions Associated With One or More Local Non-serious Adverse Events (Non-SAEs)</title>
          <description>The number of infusions associated with local non-SAEs divided by the total number of infusions.</description>
          <population>Safety Analysis Set</population>
          <units>Percent of infusions</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)</title>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting One or More Local Non-serious Adverse Events (Non-SAEs)</title>
          <population>Safety Analysis Set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</title>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</title>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion rate reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion stopped</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</title>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants for Whom the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped Due to Tolerability Concerns or AEs</title>
          <population>Safety Analysis Set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion rate reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion interrupted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion stopped</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration</title>
        <description>An infusion will be deemed as tolerated unless one of the following occurs:
Any serious related AE(s)
Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion
Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infusions Tolerated With Intravenous or Subcutaneous Administration</title>
          <description>An infusion will be deemed as tolerated unless one of the following occurs:
Any serious related AE(s)
Any non-serious local or systemic related AE(s) that prevent(s) completion of infusion
Any severe non-serious local or systemic related AE(s) that occur within 60 minutes of completion of the infusion</description>
          <population>Safety Analysis Set</population>
          <units>Percent of infusions</units>
          <param>Number</param>
          <units_analyzed>Infusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Infusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="4327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term Tolerance - Change in Blood Pressure</title>
        <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term Tolerance - Change in Heart Rate (Pulse)</title>
        <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term Tolerance - Change in Respiratory Rate</title>
        <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Term Tolerance - Change in Body Temperature</title>
        <time_frame>Within 30 minutes pre-infusion, during infusion and within 30 minutes post infusion at first 3 infusions in Epoch 1 &amp; 2</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration</title>
        <description>Laboratory tests for confirmation of potential hemolysis include Coomb’s test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.</description>
        <time_frame>Epoch 1: 3 week IV interval- weeks 0, 10. Epoch 1: 4 week IV interval- weeks 0, 9. Epoch 3: Subcutaneous (SC) week 9. Epoch 4: SC weeks 17, 18, 40</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous 10%</title>
          </group>
          <group group_id="O2">
            <title>Subcutaneous 20%</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Confirmed Hemolysis That Occurred Following Investigational Product Administration</title>
          <description>Laboratory tests for confirmation of potential hemolysis include Coomb’s test, haptoglobin, free hemoglobin, reticulocyte count, lactate dehydrogenase (LDH), and urine hemosiderin.</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years</title>
        <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set (subset of participants aged 2 to 7 years)</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Study Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Study Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Study Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Study Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End Epoch 1 to End Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End Epoch 1 to End Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life- Pediatric Quality of Life Inventory^TM (PEDS-QL^TM) (Observer: Parent) for the Age Group 2 to 7 Years</title>
          <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
          <population>Safety Analysis Set (subset of participants aged 2 to 7 years)</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.31" lower_limit="68.75" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.75" lower_limit="56.25" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.88" lower_limit="62.50" upper_limit="100.00"/>
                    <measurement group_id="O4" value="92.19" lower_limit="75.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="1.56" lower_limit="-3.13" upper_limit="9.38"/>
                    <measurement group_id="O6" value="1.56" lower_limit="-12.50" upper_limit="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.00" lower_limit="70.00" upper_limit="95.00"/>
                    <measurement group_id="O2" value="85.00" lower_limit="50.00" upper_limit="95.00"/>
                    <measurement group_id="O3" value="82.50" lower_limit="60.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="77.50" lower_limit="55.00" upper_limit="85.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-5.00" upper_limit="10.00"/>
                    <measurement group_id="O6" value="-2.50" lower_limit="-20.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.00" lower_limit="65.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="95.00" lower_limit="25.00" upper_limit="100.00"/>
                    <measurement group_id="O3" value="97.50" lower_limit="25.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="87.50" lower_limit="50.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-5.00" upper_limit="10.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-15.00" upper_limit="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.00" lower_limit="55.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="75.00" lower_limit="30.00" upper_limit="83.33"/>
                    <measurement group_id="O3" value="81.67" lower_limit="40.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="67.50" lower_limit="25.00" upper_limit="91.67"/>
                    <measurement group_id="O5" value="7.50" lower_limit="0.00" upper_limit="25.00"/>
                    <measurement group_id="O6" value="-5.00" lower_limit="-10.00" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosocial Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67" lower_limit="65.00" upper_limit="98.08"/>
                    <measurement group_id="O2" value="83.33" lower_limit="38.33" upper_limit="92.31"/>
                    <measurement group_id="O3" value="84.17" lower_limit="41.67" upper_limit="100.00"/>
                    <measurement group_id="O4" value="77.50" lower_limit="46.67" upper_limit="90.38"/>
                    <measurement group_id="O5" value="2.50" lower_limit="0.00" upper_limit="11.67"/>
                    <measurement group_id="O6" value="-3.33" lower_limit="-8.33" upper_limit="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.31" lower_limit="68.75" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.75" lower_limit="56.25" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.88" lower_limit="62.50" upper_limit="100.00"/>
                    <measurement group_id="O4" value="92.19" lower_limit="75.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="1.56" lower_limit="-3.13" upper_limit="9.38"/>
                    <measurement group_id="O6" value="1.56" lower_limit="-12.50" upper_limit="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.93" lower_limit="69.57" upper_limit="98.81"/>
                    <measurement group_id="O2" value="86.96" lower_limit="59.78" upper_limit="94.05"/>
                    <measurement group_id="O3" value="88.04" lower_limit="60.87" upper_limit="100.00"/>
                    <measurement group_id="O4" value="82.61" lower_limit="60.87" upper_limit="94.05"/>
                    <measurement group_id="O5" value="1.63" lower_limit="0.00" upper_limit="10.87"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-5.43" upper_limit="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age</title>
        <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set participants aged 8 to 13 with scores at each respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End of Epoch 1 to End of Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End of Epoch 1 to End of Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life- PEDS-QL^TM (Observer: Participant) for the Age Group 8 to 13 Years of Age</title>
          <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. Higher scores indicate better quality of life (QoL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored. 2 summary scores (Psychosocial Health Summary, and Physical Health Summary) are presented, along with a total score.</description>
          <population>Safety Analysis Set participants aged 8 to 13 with scores at each respective time point.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.06" lower_limit="81.25" upper_limit="100.00"/>
                    <measurement group_id="O2" value="90.63" lower_limit="78.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="87.50" lower_limit="75.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="93.75" lower_limit="71.88" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-3.13" upper_limit="9.38"/>
                    <measurement group_id="O6" value="6.25" lower_limit="0.00" upper_limit="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="75.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="80.00" lower_limit="70.00" upper_limit="90.00"/>
                    <measurement group_id="O3" value="80.00" lower_limit="70.00" upper_limit="95.00"/>
                    <measurement group_id="O4" value="87.50" lower_limit="65.00" upper_limit="95.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-5.00" upper_limit="5.00"/>
                    <measurement group_id="O6" value="10.00" lower_limit="-5.00" upper_limit="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" lower_limit="80.00" upper_limit="100.00"/>
                    <measurement group_id="O2" value="95.00" lower_limit="80.00" upper_limit="100.00"/>
                    <measurement group_id="O3" value="95.00" lower_limit="85.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="95.00" lower_limit="85.00" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="5.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="55.00" upper_limit="90.00"/>
                    <measurement group_id="O2" value="80.00" lower_limit="60.00" upper_limit="85.00"/>
                    <measurement group_id="O3" value="75.00" lower_limit="55.00" upper_limit="85.00"/>
                    <measurement group_id="O4" value="70.00" lower_limit="55.00" upper_limit="85.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-10.00" upper_limit="10.00"/>
                    <measurement group_id="O6" value="-2.50" lower_limit="-15.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosocial Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.83" lower_limit="76.67" upper_limit="91.67"/>
                    <measurement group_id="O2" value="83.33" lower_limit="71.67" upper_limit="91.67"/>
                    <measurement group_id="O3" value="81.67" lower_limit="75.00" upper_limit="93.33"/>
                    <measurement group_id="O4" value="81.67" lower_limit="78.33" upper_limit="91.67"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-3.33" upper_limit="8.33"/>
                    <measurement group_id="O6" value="3.33" lower_limit="-1.67" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.06" lower_limit="81.25" upper_limit="100.00"/>
                    <measurement group_id="O2" value="90.63" lower_limit="78.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="87.50" lower_limit="75.00" upper_limit="100.00"/>
                    <measurement group_id="O4" value="93.75" lower_limit="71.88" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-3.13" upper_limit="9.38"/>
                    <measurement group_id="O6" value="6.25" lower_limit="0.00" upper_limit="15.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.41" lower_limit="82.61" upper_limit="94.57"/>
                    <measurement group_id="O2" value="89.13" lower_limit="69.57" upper_limit="91.30"/>
                    <measurement group_id="O3" value="81.52" lower_limit="76.09" upper_limit="93.48"/>
                    <measurement group_id="O4" value="85.87" lower_limit="79.35" upper_limit="92.39"/>
                    <measurement group_id="O5" value="1.09" lower_limit="-1.09" upper_limit="7.61"/>
                    <measurement group_id="O6" value="2.17" lower_limit="-3.26" upper_limit="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older</title>
        <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set participants aged 14 years and older with scores at each respective time point.</population>
        <group_list>
          <group group_id="O1">
            <title>START OF STUDY EPOCH 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>END OF STUDY EPOCH 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>END OF STUDY EPOCH 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>END OF STUDY EPOCH 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>CHANGE END EPOCH 1 TO END EPOCH 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>CHANGE END EPOCH 1 TO END EPOCH 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life- Short-Form 36v2 (SF-36v2) for the Age Group 14 Years and Older</title>
          <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both sub-scores and summary scores.</description>
          <population>Safety Analysis Set participants aged 14 years and older with scores at each respective time point.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.61" lower_limit="46.51" upper_limit="52.82"/>
                    <measurement group_id="O2" value="52.82" lower_limit="44.41" upper_limit="54.93"/>
                    <measurement group_id="O3" value="50.72" lower_limit="48.61" upper_limit="52.82"/>
                    <measurement group_id="O4" value="50.72" lower_limit="46.51" upper_limit="54.93"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-2.10" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-2.10" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.61" lower_limit="37.26" upper_limit="49.51"/>
                    <measurement group_id="O2" value="42.16" lower_limit="37.26" upper_limit="51.96"/>
                    <measurement group_id="O3" value="49.51" lower_limit="42.16" upper_limit="54.40"/>
                    <measurement group_id="O4" value="47.06" lower_limit="44.61" upper_limit="51.96"/>
                    <measurement group_id="O5" value="2.45" lower_limit="0.00" upper_limit="4.90"/>
                    <measurement group_id="O6" value="2.45" lower_limit="0.00" upper_limit="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.95" lower_limit="41.41" upper_limit="51.13"/>
                    <measurement group_id="O2" value="45.64" lower_limit="37.18" upper_limit="50.29"/>
                    <measurement group_id="O3" value="50.29" lower_limit="41.83" upper_limit="51.13"/>
                    <measurement group_id="O4" value="46.06" lower_limit="41.83" upper_limit="51.13"/>
                    <measurement group_id="O5" value="4.23" lower_limit="0.00" upper_limit="4.65"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.63" lower_limit="33.87" upper_limit="41.02"/>
                    <measurement group_id="O2" value="41.02" lower_limit="33.87" upper_limit="44.83"/>
                    <measurement group_id="O3" value="38.63" lower_limit="36.25" upper_limit="45.78"/>
                    <measurement group_id="O4" value="38.63" lower_limit="36.25" upper_limit="45.78"/>
                    <measurement group_id="O5" value="0.95" lower_limit="-1.43" upper_limit="2.38"/>
                    <measurement group_id="O6" value="0.72" lower_limit="-2.38" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.72" lower_limit="39.60" upper_limit="48.97"/>
                    <measurement group_id="O2" value="42.72" lower_limit="36.48" upper_limit="48.97"/>
                    <measurement group_id="O3" value="45.85" lower_limit="39.60" upper_limit="52.09"/>
                    <measurement group_id="O4" value="48.97" lower_limit="42.72" upper_limit="52.09"/>
                    <measurement group_id="O5" value="3.12" lower_limit="0.00" upper_limit="3.12"/>
                    <measurement group_id="O6" value="1.56" lower_limit="0.00" upper_limit="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.94" lower_limit="40.49" upper_limit="51.40"/>
                    <measurement group_id="O2" value="45.94" lower_limit="40.49" upper_limit="51.40"/>
                    <measurement group_id="O3" value="51.40" lower_limit="45.94" upper_limit="51.40"/>
                    <measurement group_id="O4" value="51.40" lower_limit="45.94" upper_limit="56.85"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.99" lower_limit="44.22" upper_limit="55.88"/>
                    <measurement group_id="O2" value="55.88" lower_limit="48.10" upper_limit="55.88"/>
                    <measurement group_id="O3" value="51.99" lower_limit="48.10" upper_limit="55.88"/>
                    <measurement group_id="O4" value="53.94" lower_limit="44.22" upper_limit="55.88"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.01" lower_limit="47.19" upper_limit="52.82"/>
                    <measurement group_id="O2" value="52.82" lower_limit="47.19" upper_limit="55.64"/>
                    <measurement group_id="O3" value="50.01" lower_limit="47.19" upper_limit="52.82"/>
                    <measurement group_id="O4" value="52.82" lower_limit="50.01" upper_limit="55.64"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-2.82" upper_limit="2.82"/>
                    <measurement group_id="O6" value="1.41" lower_limit="-2.82" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.57" lower_limit="38.01" upper_limit="47.02"/>
                    <measurement group_id="O2" value="39.93" lower_limit="37.57" upper_limit="47.98"/>
                    <measurement group_id="O3" value="46.13" lower_limit="43.00" upper_limit="50.84"/>
                    <measurement group_id="O4" value="46.07" lower_limit="42.38" upper_limit="49.25"/>
                    <measurement group_id="O5" value="1.22" lower_limit="-0.51" upper_limit="3.29"/>
                    <measurement group_id="O6" value="0.89" lower_limit="-0.37" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.92" lower_limit="45.53" upper_limit="51.78"/>
                    <measurement group_id="O2" value="49.45" lower_limit="46.87" upper_limit="53.58"/>
                    <measurement group_id="O3" value="49.70" lower_limit="46.37" upper_limit="54.06"/>
                    <measurement group_id="O4" value="51.59" lower_limit="48.03" upper_limit="54.35"/>
                    <measurement group_id="O5" value="0.57" lower_limit="-2.17" upper_limit="2.39"/>
                    <measurement group_id="O6" value="1.31" lower_limit="-3.69" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old</title>
        <description>TSQM; for the age group 2 to 12 years the observer will be a parent.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant’s satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set - participants aged 2-12 years old with data (scores) at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End of Epoch 1 to End of Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End of Epoch 1 to End of Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Questionnaire for Medication (TSQM) - 2 to 12 Years Old</title>
          <description>TSQM; for the age group 2 to 12 years the observer will be a parent.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant’s satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
          <population>Safety Analysis Set - participants aged 2-12 years old with data (scores) at relevant time points</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effectiveness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" lower_limit="77.78" upper_limit="100.00"/>
                    <measurement group_id="O2" value="88.89" lower_limit="83.33" upper_limit="100.00"/>
                    <measurement group_id="O3" value="83.33" lower_limit="66.67" upper_limit="100.00"/>
                    <measurement group_id="O4" value="91.67" lower_limit="72.22" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="-11.11" upper_limit="0.00"/>
                    <measurement group_id="O6" value="0.00" lower_limit="-5.56" upper_limit="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="55.56" upper_limit="88.89"/>
                    <measurement group_id="O2" value="72.22" lower_limit="66.67" upper_limit="83.33"/>
                    <measurement group_id="O3" value="80.56" lower_limit="77.78" upper_limit="100.00"/>
                    <measurement group_id="O4" value="77.78" lower_limit="77.78" upper_limit="94.44"/>
                    <measurement group_id="O5" value="5.56" lower_limit="0.00" upper_limit="27.78"/>
                    <measurement group_id="O6" value="5.56" lower_limit="0.00" upper_limit="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.71" lower_limit="78.57" upper_limit="100.00"/>
                    <measurement group_id="O2" value="92.86" lower_limit="71.43" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="71.43" upper_limit="100.00"/>
                    <measurement group_id="O4" value="89.29" lower_limit="71.43" upper_limit="100.00"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="7.14"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older</title>
        <description>TSQM; for the age group 13 years and older the observer will be the participant.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant’s satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set - participants aged 13 years and older with data (scores) at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End of Epoch 1 to End of Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End of Epoch 1 to End of Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction Questionnaire for Medication (TSQM) - 13 Years and Older</title>
          <description>TSQM; for the age group 13 years and older the observer will be the participant.
Treatment Satisfaction Questionnaire for Medication (TSQM) is a global satisfaction scale used to assess the overall level of participant’s satisfaction or dissatisfaction with their medications. The following 3 domain were included: effectiveness, convenience, and global satisfaction.
The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
          <population>Safety Analysis Set - participants aged 13 years and older with data (scores) at relevant time points</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effectiveness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78" lower_limit="72.22" upper_limit="83.33"/>
                    <measurement group_id="O2" value="80.56" lower_limit="72.22" upper_limit="88.89"/>
                    <measurement group_id="O3" value="83.33" lower_limit="77.78" upper_limit="88.89"/>
                    <measurement group_id="O4" value="83.33" lower_limit="77.78" upper_limit="88.89"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="5.56"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="61.11" upper_limit="77.78"/>
                    <measurement group_id="O2" value="66.67" lower_limit="55.56" upper_limit="72.22"/>
                    <measurement group_id="O3" value="83.33" lower_limit="72.22" upper_limit="83.33"/>
                    <measurement group_id="O4" value="83.33" lower_limit="77.78" upper_limit="88.89"/>
                    <measurement group_id="O5" value="11.11" lower_limit="5.56" upper_limit="16.67"/>
                    <measurement group_id="O6" value="11.11" lower_limit="5.56" upper_limit="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.71" lower_limit="78.57" upper_limit="92.86"/>
                    <measurement group_id="O2" value="85.71" lower_limit="78.57" upper_limit="92.86"/>
                    <measurement group_id="O3" value="92.86" lower_limit="78.57" upper_limit="92.86"/>
                    <measurement group_id="O4" value="92.86" lower_limit="85.71" upper_limit="92.86"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="7.14"/>
                    <measurement group_id="O6" value="0.00" lower_limit="0.00" upper_limit="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Quality Index - 2 to 12 Years Old</title>
        <description>For the age group 2 to 12 years the respondent will be a parent.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
        <time_frame>Up to 20 months (throughout entire study)</time_frame>
        <population>Safety Analysis Set - participants aged 2-12 years old with data (scores) at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End of Epoch 1 to End of Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End of Epoch 1 to End of Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Life Quality Index - 2 to 12 Years Old</title>
          <description>For the age group 2 to 12 years the respondent will be a parent.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
          <population>Safety Analysis Set - participants aged 2-12 years old with data (scores) at relevant time points</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="27.0" upper_limit="40.0"/>
                    <measurement group_id="O2" value="31.0" lower_limit="30.0" upper_limit="41.0"/>
                    <measurement group_id="O3" value="35.0" lower_limit="31.0" upper_limit="39.0"/>
                    <measurement group_id="O4" value="34.5" lower_limit="30.0" upper_limit="39.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-2.0" upper_limit="5.0"/>
                    <measurement group_id="O6" value="-0.5" lower_limit="-2.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy-related Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="20.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="23.0" lower_limit="22.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="22.0" lower_limit="20.0" upper_limit="24.0"/>
                    <measurement group_id="O4" value="21.5" lower_limit="21.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-2.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="-1.0" lower_limit="-3.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy Settings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="17.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="18.0" lower_limit="16.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="19.0" lower_limit="18.0" upper_limit="21.0"/>
                    <measurement group_id="O4" value="20.0" lower_limit="17.0" upper_limit="21.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="-1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.0" upper_limit="11.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="10.0" upper_limit="13.0"/>
                    <measurement group_id="O3" value="11.0" lower_limit="11.0" upper_limit="12.0"/>
                    <measurement group_id="O4" value="10.5" lower_limit="9.0" upper_limit="13.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O6" value="-0.5" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Quality Index - 13 Years and Older</title>
        <description>For the age group 13 years and older the respondent will be the participant.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
        <time_frame>Up to 20 months per subject (throughout entire study)</time_frame>
        <population>Safety Analysis Set - participants aged 13 years and older with data (scores) at relevant time points</population>
        <group_list>
          <group group_id="O1">
            <title>Start of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O2">
            <title>End of Epoch 1</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.</description>
          </group>
          <group group_id="O3">
            <title>End of Epoch 3</title>
            <description>Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O4">
            <title>End of Epoch 4</title>
            <description>Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
          <group group_id="O5">
            <title>Change End of Epoch 1 to End of Epoch 3</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.</description>
          </group>
          <group group_id="O6">
            <title>Change End of Epoch 1 to End of Epoch 4</title>
            <description>Epoch 1 (13 weeks): Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study. Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Life Quality Index - 13 Years and Older</title>
          <description>For the age group 13 years and older the respondent will be the participant.
Each of the four domains has a separate score, each has a different range as follows:
Treatment Interference Score Range: 6-42, Therapy-related Problems Score Range: 4-28, Therapy Setting Score Range: 3-21, Cost Score Range: 2-14. Higher scores represent more satisfaction with various aspects of treatment.</description>
          <population>Safety Analysis Set - participants aged 13 years and older with data (scores) at relevant time points</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="30.0" upper_limit="37.0"/>
                    <measurement group_id="O2" value="34.5" lower_limit="32.0" upper_limit="36.0"/>
                    <measurement group_id="O3" value="37.0" lower_limit="35.0" upper_limit="39.0"/>
                    <measurement group_id="O4" value="38.5" lower_limit="34.0" upper_limit="40.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="O6" value="3.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy-related Problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="22.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="22.5" lower_limit="21.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="24.0" lower_limit="22.0" upper_limit="25.0"/>
                    <measurement group_id="O4" value="24.0" lower_limit="23.0" upper_limit="25.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-1.0" upper_limit="2.0"/>
                    <measurement group_id="O6" value="1.0" lower_limit="-1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapy Settings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="16.0" upper_limit="19.0"/>
                    <measurement group_id="O2" value="17.0" lower_limit="16.0" upper_limit="18.0"/>
                    <measurement group_id="O3" value="20.0" lower_limit="19.0" upper_limit="20.0"/>
                    <measurement group_id="O4" value="20.0" lower_limit="19.0" upper_limit="21.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O6" value="2.0" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Costs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="7.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="10.0" lower_limit="9.0" upper_limit="10.0"/>
                    <measurement group_id="O3" value="11.5" lower_limit="10.0" upper_limit="13.0"/>
                    <measurement group_id="O4" value="13.0" lower_limit="11.0" upper_limit="14.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the 4 Study Epochs. Epoch 1: 13 weeks. Epoch 2: 12-16 weeks Epoch 3: 12 weeks Epoch 4: 40 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Epoch 1: Intravenous 10% Treatment</title>
        </group>
        <group group_id="E2">
          <title>Study Epochs 2-4: Subcutaneous 20% Treatment</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinima</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="21" subjects_affected="11" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="34" subjects_affected="14" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="23" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="29" subjects_affected="18" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" events="21" subjects_affected="14" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="44" subjects_affected="23" subjects_at_risk="77"/>
                <counts group_id="E2" events="54" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="15" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or ≤15 months after study completion. Baxalta requires a review of results communications (eg, for confidential information) ≥30 days prior to submission or communication. Baxalta may request an additional delay of ≤60 days eg, for intellectual property protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Leman Yel, Senior Medical Director</name_or_title>
      <organization>Baxalta, now part of Shire</organization>
      <email>leman.yel@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

